JP7871265B2 - 抗b7-h3抗体およびその使用 - Google Patents
抗b7-h3抗体およびその使用Info
- Publication number
- JP7871265B2 JP7871265B2 JP2023539061A JP2023539061A JP7871265B2 JP 7871265 B2 JP7871265 B2 JP 7871265B2 JP 2023539061 A JP2023539061 A JP 2023539061A JP 2023539061 A JP2023539061 A JP 2023539061A JP 7871265 B2 JP7871265 B2 JP 7871265B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- antibody
- sequence shown
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011544445 | 2020-12-23 | ||
| CN202011544445.8 | 2020-12-23 | ||
| PCT/CN2021/140449 WO2022135467A1 (zh) | 2020-12-23 | 2021-12-22 | 抗b7-h3抗体及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024500512A JP2024500512A (ja) | 2024-01-09 |
| JP2024500512A5 JP2024500512A5 (cg-RX-API-DMAC7.html) | 2025-01-07 |
| JP7871265B2 true JP7871265B2 (ja) | 2026-06-08 |
Family
ID=82157408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539061A Active JP7871265B2 (ja) | 2020-12-23 | 2021-12-22 | 抗b7-h3抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240043540A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4269435A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7871265B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230124959A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117098548A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021407023B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203257A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022135467A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119948063A (zh) * | 2022-06-23 | 2025-05-06 | 信达生物制药(苏州)有限公司 | 结合egfr和b7-h3的双特异性抗体 |
| WO2024007129A1 (zh) * | 2022-07-04 | 2024-01-11 | 英诺湖医药(杭州)有限公司 | 人源化的b7h3抗体或其抗原结合片段 |
| CN119925631A (zh) * | 2023-11-03 | 2025-05-06 | 信达生物制药(苏州)有限公司 | 靶向b7-h3的抗体-药物偶联物及其用途 |
| WO2025131054A1 (en) * | 2023-12-22 | 2025-06-26 | Innovent Biologics (Suzhou) Co., Ltd. | Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013520994A (ja) | 2010-03-04 | 2013-06-10 | マクロジェニクス,インコーポレーテッド | B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| JP2017532952A (ja) | 2014-08-27 | 2017-11-09 | メモリアル スローン−ケタリング キャンサー センター | 抗体、組成物および使用 |
| WO2018161872A1 (zh) | 2017-03-06 | 2018-09-13 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
| WO2019024911A1 (zh) | 2017-08-04 | 2019-02-07 | 江苏恒瑞医药股份有限公司 | B7h3抗体-药物偶联物及其医药用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2703486B1 (en) * | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| US10865245B2 (en) * | 2014-12-23 | 2020-12-15 | Full Spectrum Genetics, Inc. | Anti-B7H3 binding compounds and uses thereof |
| RS61828B1 (sr) * | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
| WO2020094120A1 (zh) * | 2018-11-09 | 2020-05-14 | 上海复旦张江生物医药股份有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
| CN109851673B (zh) * | 2019-01-22 | 2023-07-25 | 苏州旭光科星抗体生物科技有限公司 | 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒 |
| CN111944050B (zh) * | 2020-08-19 | 2022-05-13 | 苏州普乐康医药科技有限公司 | 一种抗b7-h3抗体及其应用 |
-
2021
- 2021-12-22 CA CA3203257A patent/CA3203257A1/en active Pending
- 2021-12-22 JP JP2023539061A patent/JP7871265B2/ja active Active
- 2021-12-22 CN CN202180086116.XA patent/CN117098548A/zh active Pending
- 2021-12-22 AU AU2021407023A patent/AU2021407023B2/en active Active
- 2021-12-22 EP EP21909462.0A patent/EP4269435A4/en active Pending
- 2021-12-22 WO PCT/CN2021/140449 patent/WO2022135467A1/zh not_active Ceased
- 2021-12-22 US US18/258,576 patent/US20240043540A1/en active Pending
- 2021-12-22 KR KR1020237023796A patent/KR20230124959A/ko active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013520994A (ja) | 2010-03-04 | 2013-06-10 | マクロジェニクス,インコーポレーテッド | B7−h3と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| JP2017532952A (ja) | 2014-08-27 | 2017-11-09 | メモリアル スローン−ケタリング キャンサー センター | 抗体、組成物および使用 |
| WO2018161872A1 (zh) | 2017-03-06 | 2018-09-13 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
| WO2019024911A1 (zh) | 2017-08-04 | 2019-02-07 | 江苏恒瑞医药股份有限公司 | B7h3抗体-药物偶联物及其医药用途 |
Non-Patent Citations (1)
| Title |
|---|
| J Biol Chem,2015年,vol.290, no.50,p.30018-30029 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021407023A1 (en) | 2023-07-20 |
| EP4269435A1 (en) | 2023-11-01 |
| EP4269435A4 (en) | 2025-06-18 |
| CN117098548A (zh) | 2023-11-21 |
| JP2024500512A (ja) | 2024-01-09 |
| WO2022135467A1 (zh) | 2022-06-30 |
| US20240043540A1 (en) | 2024-02-08 |
| KR20230124959A (ko) | 2023-08-28 |
| CA3203257A1 (en) | 2022-06-30 |
| AU2021407023B2 (en) | 2025-12-04 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230915 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230915 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230915 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260428 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260527 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7871265 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |